118 related articles for article (PubMed ID: 7499442)
21. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
Kelly K; Crowley J; Bunn PA; Presant CA; Grevstad PK; Moinpour CM; Ramsey SD; Wozniak AJ; Weiss GR; Moore DF; Israel VK; Livingston RB; Gandara DR
J Clin Oncol; 2001 Jul; 19(13):3210-8. PubMed ID: 11432888
[TBL] [Abstract][Full Text] [Related]
22. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
Panday VR; van Warmerdam LJ; Huizing MT; Rodenhuis S; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 1999; 43(5):435-8. PubMed ID: 10100601
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.
Dittrich C; Sevelda P; Baur M; Marth C; Hudec M; Vavra N; Grunt T; Fazeny B; Salzer H
Cancer; 1993 May; 71(10):3082-90. PubMed ID: 8490836
[TBL] [Abstract][Full Text] [Related]
24. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.
Los G; Verdegaal EM; Mutsaers PH; McVie JG
Cancer Chemother Pharmacol; 1991; 28(3):159-65. PubMed ID: 1855272
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
26. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
[TBL] [Abstract][Full Text] [Related]
27. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.
Gomi K; Ohno H; Nomura K; Okabe M; Kobayashi K; Niitani H
Jpn J Cancer Res; 1992 May; 83(5):532-9. PubMed ID: 1618703
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Huizing MT; Giaccone G; van Warmerdam LJ; Rosing H; Bakker PJ; Vermorken JB; Postmus PE; van Zandwijk N; Koolen MG; ten Bokkel Huinink WW; van der Vijgh WJ; Bierhorst FJ; Lai A; Dalesio O; Pinedo HM; Veenhof CH; Beijnen JH
J Clin Oncol; 1997 Jan; 15(1):317-29. PubMed ID: 8996159
[TBL] [Abstract][Full Text] [Related]
29. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
31. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacology of carboplatin administered in combination with paclitaxel.
van Warmerdam LJ; Huizing MT; Giaccone G; Postmus PE; ten Bokkel Huinink WW; van Zandwijk N; Koolen MG; Helmerhorst TJ; van der Vijgh WJ; Veenhof CH; Beijnen JH
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-97-S2-104. PubMed ID: 9045347
[TBL] [Abstract][Full Text] [Related]
33. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
Pisano C; Vesci L; Milazzo FM; Guglielmi MB; Foderà R; Barbarino M; D'Incalci M; Zucchetti M; Petrangolini G; Tortoreto M; Perego P; Zuco V; Orlandi A; Passeri D; Carminati P; Cavazza C; Zunino F
Clin Cancer Res; 2010 Aug; 16(15):3944-53. PubMed ID: 20562210
[TBL] [Abstract][Full Text] [Related]
34. Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519.
Nakamura T; Koizumi F; Kaneko N; Tamura T; Chiwaki F; Koh Y; Akutagawa S; Saijo N; Nishio K
Jpn J Cancer Res; 2001 Jun; 92(6):597-602. PubMed ID: 11429046
[TBL] [Abstract][Full Text] [Related]
35. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
[TBL] [Abstract][Full Text] [Related]
36. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Grènman S
Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of administration of a combination of docetaxel and carboplatin for advanced non-small cell lung cancer.
Bando H; Miyata J; Sano T; Sumitomo M
Anticancer Res; 2001; 21(3C):2107-13. PubMed ID: 11501833
[TBL] [Abstract][Full Text] [Related]
38. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
39. Synergistic cytotoxicity of ampelopsin sodium and carboplatin in human non-small cell lung cancer cell line SPC-A1 by G
Lu L; Yang LN; Wang XX; Song CL; Qin H; Wu YJ
Chin J Integr Med; 2017 Feb; 23(2):125-131. PubMed ID: 27299463
[TBL] [Abstract][Full Text] [Related]
40. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
Socinski MA; Shea TC
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
